3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
1
Conditions
Lymphoma
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Mantle-Cell
5
Waldenstrom Macroglobulinemia
4
Multiple Myeloma
3
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Leukemia, Biphenotypic, Acute
2
Hematologic Neoplasms
2
Recurrence
1
Plasmablastic Lymphoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Burkitt Lymphoma
1
Amyloidosis
1
Interventions
venetoclax
1
ixazomib
1
Interleukin-2
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Antineoplastic Protocols
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Amyloidosis
×
ixazomib
×
Lymphoid
×
Clear all
NCT02924272
2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2
Completed
32 enrolled
13 charts